Jay Bradner, president of the Novartis Institutes for Biomedical Research (NIBR), is retiring from the position after seven years in the role, and will be replaced by Merck & Co R&D executive ...

Then in October the company unveiled a major restructuring of its global R&D organisation, led from its headquarters in Basel, Switzerland and the Novartis Institutes for BioMedical Research (NIBR ...

Previously, Dr. Sellers directed cancer drug discovery and early cancer clinical development at the Novartis Institutes for ...

Sangamo Therapeutics, Inc.’s SGMO share price has dipped by 13.07%, which has investors questioning if this is right time to ...

This is Novartis’s third U.S. approval for its kidney disease portfolio in the last year. Fabhalta was granted FDA approval in C3 glomerulopathy in March 2025 and accelerated approval in IgAN in ...

Novartis' Vanrafia reduced proteinuria by 36.1% in IgAN patients using a RAS inhibitor. Continued FDA approval depends on Phase 3 ALIGN study results in 2026. Feel unsure about the market’s next ...

Novartis (NYSE:NVS) said on Thursday that it received US FDA's accelerated approval for Vanrafia as a treatment for adults with primary immunoglobulin A nephropathy at high risk of rapid disease ...

Novartis (NVS) “announced the FDA has granted accelerated approval for Vanrafia, or atrasentan, a potent and selective endothelin A receptor antagonist, for the reduction of proteinuria in ...

Building on a 40-year legacy that began in transplant, Novartis is on a mission to empower breakthroughs and transform care in kidney health, starting with kidney conditions that have significant ...

(Image Credits: Pixabay) Novartis on Thursday announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia (atrasentan) to treat primary immunoglobulin A ...